<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336424</url>
  </required_header>
  <id_info>
    <org_study_id>FM292</org_study_id>
    <nct_id>NCT03336424</nct_id>
  </id_info>
  <brief_title>Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations.</brief_title>
  <official_title>Prospective Randomized Controlled Trial Comparing the Non-invasive vs the Invasive Investigations in Multiple Sclerosis Patients With Urinary Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint-Joseph University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saint-Joseph University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to describe the current status of MS patients with urinary
      disorders in Lebanon, and to demonstrate whether invasive investigations improve the
      management of these patients compared to an optimal non-invasive approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will be evaluated by an urologist, then randomized into 2 groups, the first
      group will benefit from non-invasive investigations and will be treated accordingly, the
      second group will benefit from an urodynamic assessment and will also be treated accordingly.

      An evaluation will be made one month, 3 months and 6 months after the first visit.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel study, where group A receives non-invasive investigations and group B receives Invasive investigations.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>filling and voiding urinary symptoms (UBQMS: Urinary Bothersome Questionnaire in Multiple Sclerosis), Voising Score Ranges from 0 to 3 ( 3 being most severe bother), Filling score ranges from 0 to 3 ( 3 being most severe bother).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urinary quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>SF-QUALIVEEN: Short Form - health related quality of life questionnaire for urinary disorders in patients with neurological conditions. score ranges from 0 to 4 ( 4 being the worst quality of life).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Urinary Bladder, Neurogenic</condition>
  <condition>Urodynamics</condition>
  <arm_group>
    <arm_group_label>Non-invasive investigations group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-invasive investigations include: ultrasound, blood exam, urine analysis and culture, uroflowmetry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Invasive investigations group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>urodynamic study including: cystomanometry, pressure flow study, EMG</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Non-invasive investigations</intervention_name>
    <description>Ultrasound, blood tests, urine analysis and culture, uroflowmetry</description>
    <arm_group_label>Non-invasive investigations group</arm_group_label>
    <arm_group_label>Invasive investigations group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Invasive investigations</intervention_name>
    <description>Cystomanometry, pressure flow study, EMG</description>
    <arm_group_label>Invasive investigations group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MS with urinary symptoms

        Exclusion Criteria:

          -  BPH LUTS

          -  Bladder cancer

          -  prostate cancer

          -  urethral stenosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie EL HELOU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Joseph University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Joseph University</name>
      <address>
        <city>Beyrouth</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2017</study_first_submitted>
  <study_first_submitted_qc>November 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>December 2, 2017</last_update_submitted>
  <last_update_submitted_qc>December 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>Multiple sclerosis</keyword>
  <keyword>urinary Bladder, Neurogenic</keyword>
  <keyword>Urodynamics</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

